Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis
- Authors
- Choi, S-J; Kwak, D. W.; Kil, K.; Kim, S-C; Kwon, J-Y; Kim, Y. H.; Na, S.; Bae, J-G; Cha, H-H; Shim, J-Y; Oh, K. Y.; Lee, K. A.; Kim, S. M.; Cho, I. A.; Lee, S. M.; Cho, G. J.; Jo, Y. S.; Choi, G. Y.; Choi, S. K.; Hur, S. E.; Hwang, H. S.; Kim, Y. J.
- Issue Date
- Dec-2020
- Publisher
- Blackwell Publishing Inc.
- Keywords
- Preterm birth; prevention; progestogen; short cervical length
- Citation
- BJOG: An International Journal of Obstetrics and Gynaecology, v.127, no.13, pp 1646 - 1654
- Pages
- 9
- Journal Title
- BJOG: An International Journal of Obstetrics and Gynaecology
- Volume
- 127
- Number
- 13
- Start Page
- 1646
- End Page
- 1654
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2304
- DOI
- 10.1111/1471-0528.16365
- ISSN
- 1470-0328
1471-0528
- Abstract
- Objective To compare the efficacy of two types of progestogen therapy for preventing preterm birth (PTB) and to review the relevant literature. Design A multicentre, randomised, open-label, equivalence trial and a meta-analysis. Setting Tertiary referral hospitals in South Korea. Population Pregnant women with a history of spontaneous PTB or short cervical length (<25 mm). Methods Eligible women were screened and randomised at 16-22 weeks of gestation to receive either 200 mg of vaginal micronised progesterone daily (vaginal group) or an intramuscular injection of 250 mg 17 alpha-hydroxyprogesterone caproate weekly (IM group). Stratified randomisation was carried out according to participating centres and indications for progestogen therapy. This trial was registered at (NCT02304237). Main outcome measure Preterm birth (PTB) before 37 weeks of gestation. Results A total of 266 women were randomly assigned and a total of 247 women (119 and 128 women in the vaginal and IM groups, respectively) were available for the intention-to-treat analysis. Risks of PTB before 37 weeks of gestation did not significantly differ between the two groups (22.7 versus 25.8%,P = 0.571). The difference in PTB risk between the two groups was 3.1% (95% CI -7.6 to 13.8%), which was within the equivalence margin of 15%. The meta-analysis results showed no significant differences in the risk of PTB between the vaginal and IM progestogen treatments. Conclusion Compared with vaginal progesterone, treatment with intramuscular progestin might increase the risk of PTB before 37 weeks of gestation by as much as 13.8%, or reduce the risk by as much as 7.6%, in women with a history of spontaneous PTB or with short cervical length. Tweetable abstract Vaginal and intramuscular progestogen showed equivalent efficacy for preventing preterm birth before 37 weeks of gestation.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of obstetrics and Gynecology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2304)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.